Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference
May 24, 2021 16:05 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates
May 11, 2021 16:05 ET | Tarsus Pharmaceuticals, Inc
Initiated Saturn-2, second pivotal Phase 3 trial evaluating the safety and efficacy of TP-03 for the treatment of Demodex blepharitis; topline data from Saturn-1 expected this July Announced FDA...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals, Inc. Initiates Saturn-2, Second Pivotal Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis
May 06, 2021 16:05 ET | Tarsus Pharmaceuticals, Inc
Demodex blepharitis may affect up to 25 million Americans and result in significant clinical, functional and psychosocial burden for patients Saturn-2 trial design similar to Saturn-1, first pivotal...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention
May 04, 2021 16:05 ET | Tarsus Pharmaceuticals, Inc
Novel candidate in development aims to be first approved non-vaccine therapeutic for Lyme disease prevention Allows initiation of Phase 1 study to evaluate safety, pharmacokinetics, and dosing More...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis
May 03, 2021 16:08 ET | Tarsus Pharmaceuticals, Inc
Demodex blepharitis is a common ocular condition that may affect up to 25 million Americans Atlas study shows that Demodex blepharitis negatively impacts daily life for 80 percent of patients ...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference
April 27, 2021 16:05 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates
March 31, 2021 16:05 ET | Tarsus Pharmaceuticals, Inc
Enrollment complete for Saturn-1, first TP-03 pivotal trial for the treatment of Demodex blepharitis; initiation of Saturn-2 expected in Q2 2021 Strategic partnership with LianBio in March 2021 for...
Tarsus_Logo_Parnership_Announcement.jpg
Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease
March 29, 2021 16:05 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., SHANGHAI, China and PRINCETON, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company, and LianBio, a...
Bryan Wahl MD JD_General Counsel_Tarsus
Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel
January 19, 2021 08:30 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...
Dianne Whitfield2
Tarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources Officer
January 07, 2021 09:24 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough...